Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

INTRODUCTION: In oncology, anti-drug antibody (ADA) development that significantly curtails response durability has not historically risen to a level of concern. The relevance and attention ascribed to ADAs in oncology clinical studies have therefore been limited, and the extant literature on this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Penny, Hweixian Leong, Hainline, Kelly, Theoharis, Nathaniel, Wu, Bin, Brandl, Christian, Webhofer, Christian, McComb, Mason, Wittemer-Rump, Sabine, Koca, Gökben, Stienen, Sabine, Bargou, Ralf C., Hummel, Horst-Dieter, Loidl, Wolfgang, Grüllich, Carsten, Eggert, Tobias, Tran, Ben, Mytych, Daniel T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628759/
https://www.ncbi.nlm.nih.gov/pubmed/37942314
http://dx.doi.org/10.3389/fimmu.2023.1261070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628759/
https://www.ncbi.nlm.nih.gov/pubmed/37942314
http://dx.doi.org/10.3389/fimmu.2023.1261070

Ejemplares similares